---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-020206"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2025-05-22T23:59:59+00:00"
generated_at: "2026-05-20T18:04:02.366333+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech reports positive extended follow-up data for Versamune HPV Phase 2 in head and neck cancer

## Summary
- VERSATILE-002: mOS of 39.3 months (CPS≥20) vs ~15 months for pembrolizumab; median follow-up 18.4 months.
- mOS of 30.0 months (CPS≥1) and 29.5 months (CPS 1-19), exceeding historical pembrolizumab results.
- Phase 3 VERSATILE-003 (n=351) enrolling; primary endpoint mOS with two interim analyses planned.
- Phase 2 window trial: 70% stable disease with Versamune HPV alone; 100% SD/PR with combo; met ctDNA endpoint.

## SEC filing metadata
- accession: 0001140361-25-020206
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2025-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036125020206/0001140361-25-020206-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036125020206/ef20049600_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-020206
- JSON: https://secwatch.observer/filing/0001140361-25-020206.json
- Plain text: https://secwatch.observer/filing/0001140361-25-020206.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.